Skip to main content

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Completed · Phase 2, Phase 3 · NCT03570749

Conditions: Alopecia Areata

At a glance

Research payments reported, 2025
$189,147
U.S. investigators named
38
Sites paid
37
Planned or actual enrollment
784

About the trial

Sponsor
Eli Lilly and Company (with Incyte Corporation)
Tested
Baricitinib (drug), Placebo (drug)
Dates
Started 2018-09-24; completion 2025-01-29
Results posted
Yes

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants in the US will enroll in the open-label addenda.

From ClinicalTrials.gov, last updated 2026-04-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $189,147 in research payments for this study in 2025 (56 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.